Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave Acetate for Rubeosis Iridis
NCT00211471Phase 2Terminated
- Sponsor
- Manhattan Eye, Ear and Throat Hospital
- Start
- Mar 2002
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anecortave in rubeosis iridis (NVI), sponsored by Manhattan Eye, Ear and Throat Hospital. Primary endpoint: Investigation of the use of anecortave acetate in rubeosis iridis at 24 months. Started Mar 2002; status: terminated.
02
Drugs
anecortave
03
Conditions
rubeosis iridis (NVI)
Beyond the preview
Go deeper on NCT00211471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211471.